Showing results (751-760 of 11,014) with videos related to
Sort By:
Pageof 1,102
Annals of Neurology|January 1, 1992
Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research GroupA H Schapira, V M Mann, J M Cooper, et al.Neuroreport|October 3, 1994
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazoleG M MacKenzie, S Rose, P A Bland-Ward, et al.European Journal of Pharmacology|April 24, 1995
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmosetK K Gnanalingham, N A Milkowski, L A Smith, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 1, 1993
Alien hand sign in association with Alzheimer's histopathologyJ A Ball, P L Lantos, M Jackson, et al.Brain : a Journal of Neurology|August 1, 1991
New observations on the normal auditory startle reflex in manP Brown, J C Rothwell, P D Thompson, et al.Journal of Neural Transmission|January 1, 1985
Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugsN M Rupniak, M D Hall, E Kelly, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1991
Motor inhibition from the brainstem is normal in torsion dystonia during REM sleepD R Fish, D Sawyers, S J Smith, et al.Psychopharmacology|January 1, 1992
L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunctionK W Lange, T W Robbins, C D Marsden, et al.Neuropharmacology|August 1, 1986
MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal areaA J Bradbury, B Costall, P G Jenner, et al.Neuropharmacology|October 1, 1989
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxinA Ueki, P N Chong, A Albanese, et al.Pageof 1,102